Website News and Research

RSS

Websites bridge gaps between patients and doctors and marketers

Conveying how well a therapy works and doing so in understandable terms isn't easy, but a group of physicians is trying to change that The Wall Street Journal's Health Blog reports.

8 Oct 2010

Pioneer launches Bigfoot ALIF implant for lumbar procedures

Pioneer Surgical Technology today announces the market launch of the Pioneer Advantage portfolio of allograft products including a large ALIF interbody, Bigfoot. Pioneer Advantage products include machined allografts for cervical and anterior lumbar procedures as well as demineralized strips and cubes for use in various spinal and general orthopaedic surgeries.

7 Oct 2010

Cytori Therapeutics to sell shares of common stock in underwritten public offering

Cytori Therapeutics, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. is acting as sole book-running manager for the offering.

7 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Dr. Fresh expands social media-based initiatives to support FireFly franchise

Entertain and interact. That's the marketing mantra at Dr. Fresh, Inc. the creator of the best-selling children's FireFly toothbrush and the company behind the successful revival of the Binaca brand. The company has recently mounted a number of social media-based initiatives to support its FireFly franchise as well as other brands in its growing portfolio.

7 Oct 2010

e-IRG endorses Blue Paper at ESFRI delegates meeting

In October 2009 ESFRI invited the e-Infrastructure Reflection Group (e-IRG) to produce a report, or "Blue Paper", on e-Infrastructure services, enabling more efficient e-Infrastructure support for the science that is done by the ESFRI Roadmap projects.

7 Oct 2010

NHCAA releases new white paper to focus on health care fraud

The National Health Care Anti-Fraud Association (NHCAA) announces the release of its new white paper, Combating Health Care Fraud in a Post-Reform World Seven Guiding Principles for Policymakers.

7 Oct 2010

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

Louise A. Villejo, executive director of the Patient Education Office at The University of Texas MD Anderson Cancer Center, is the recipient of the 2010 Julie and Ben Rogers Award for Excellence in Education.

7 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

Endocrine Society urges physicians to apply new insights into the role of beta-cells in type 2 diabetes

A new consensus statement published in the September, 2010, issue of The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) finds that the increasing recognition that beta-cell failure occurs much earlier and severely than commonly believed suggests that regular glycemia screening, early identification of patients at metabolic risk and prompt and aggressive intervention deserves greater emphasis.

7 Oct 2010

NHPCO releases report on hospice care in U.S

An estimated 41.6 percent of all people who died in the U.S. last year were under the care of a hospice program, reports the National Hospice and Palliative Care Organization (up from 38.8 percent in 2008 and 35 percent in 2007).

6 Oct 2010

Pioneer Surgical receives patent for nanOss technology

Pioneer Surgical Technology, Inc., a global medical device provider in orthopaedics, spine, and biologics, is proud to announce the United States Patent Office has reissued a patent further strengthening Pioneer's market position in nanocrystalline derived products used in orthopaedics.

6 Oct 2010

AOA launches 'Break Through Your Pain' public education campaign

If you're living in pain, you're certainly not alone. According to a new survey released today by the American Osteopathic Association (AOA) nearly 70% of Americans report that they, or someone they care for, have experienced pain during the past 30 days. While Congress declared 2000 to 2010 the "Decade of Pain Control and Research," chronic, or reoccurring pain still affects more Americans than cancer, diabetes and heart disease combined. In fact, more than 76 million people live in pain every day.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.

5 Oct 2010

Celgene announces pricing of senior unsecured notes

Celgene Corporation today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion.

5 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Early diagnosis of interstitial cystitis can improve quality of life

October is interstitial cystitis (IC) awareness month and this year's campaign is dedicated to fighting discrimination.

5 Oct 2010

Study finds BRACAnalysis vital for triple negative breast cancer patients

Myriad Genetics, Inc. announced today that results from a preliminary study indicate that BRCA germline mutations occur at a high frequency in women with triple negative breast cancer, sufficiently high enough to justify screening of all women with TNBC.

5 Oct 2010

CHI submits comments to FDA CDRH 510(k) Working Group Preliminary Report and Recommendations

California Healthcare Institute today submitted formal comments to the U.S. Food and Drug Administration (FDA) regarding the Center for Devices and Radiological Health 510(k) Working Group Preliminary Report and Recommendations, which could transform the 510(k) regulatory process for new medical devices, greatly affecting innovation and public health in California. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

5 Oct 2010